INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$89.79
−0.04%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
260.8%
Return on equity
-89.6%
Return on assets
268.3%
Return on invested capital
0.00x
Asset turnover
-$131.9M
Cash from operations
$9.06
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026